Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited Return on Equity (ROE) for the year ending March 31, 2024: 9.09%

Bafna Pharmaceuticals Limited Return on Equity (ROE) is 9.09% for the year ending March 31, 2024, a -41.11% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Bafna Pharmaceuticals Limited Return on Equity (ROE) for the year ending March 31, 2023 was 15.44%, a 86.07% change year over year.
Bafna Pharmaceuticals Limited Return on Equity (ROE) for the year ending March 31, 2022 was 8.30%, a -19.17% change year over year.
Bafna Pharmaceuticals Limited Return on Equity (ROE) for the year ending March 31, 2021 was 10.26%, a 121.21% change year over year.
Bafna Pharmaceuticals Limited Return on Equity (ROE) for the year ending March 31, 2020 was -48.38%, a 51.14% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Drugstores & Retail Pharmacies Chemicals & Advanced Materials Clinical Trials Pharmaceuticals

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years